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The glutamate/cystine xCT antiporter
antagonizes glutamine metabolism
and reduces nutrient flexibility
Chun-Shik Shin1, Prashant Mishra1,2, Jeramie D. Watrous3, Valerio Carelli4,5, Marilena D’Aurelio6, Mohit Jain3
& David C. Chan1
As noted by Warburg, many cancer cells depend on the consumption of glucose. We
performed a genetic screen to identify factors responsible for glucose addiction and
recovered the two subunits of the xCT antiporter (system xc
 ), which plays an antioxidant
role by exporting glutamate for cystine. Disruption of the xCTantiporter greatly improves cell
viability after glucose withdrawal, because conservation of glutamate enables cells to
maintain mitochondrial respiration. In some breast cancer cells, xCT antiporter expression is
upregulated through the antioxidant transcription factor Nrf2 and contributes to their
requirement for glucose as a carbon source. In cells carrying patient-derived mitochondrial
DNA mutations, the xCT antiporter is upregulated and its inhibition improves mitochondrial
function and cell viability. Therefore, although upregulation of the xCT antiporter promotes
antioxidant defence, it antagonizes glutamine metabolism and restricts nutrient flexibility.
In cells with mitochondrial dysfunction, the potential utility of xCTantiporter inhibition should
be further tested.
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F
or cultured mammalian cells, the two major carbon sources
are glucose and glutamine. Catabolism of these two
nutrients generates the majority of cellular energy, building
blocks, and reducing equivalents for cell growth and proliferation.
In rapidly growing cancer cells, these metabolic demands are
accentuated, and oncogenesis often results in metabolic repro-
gramming to fuel the increase in cell biomass necessary for
constant cell divisions1–3. In the Warburg effect, the most well
studied form of metabolic reprogramming in cancer cells, aerobic
glycolysis is used to consume large amounts of glucose with
excess carbon secreted as lactate. This mode of metabolism
persists despite high enough levels of oxygen to support
oxidative phosphorylation (OXPHOS) in the mitochondria1–3.
Metabolic reprogramming allows glucose to provide biosynthetic
intermediates for the synthesis of proteins, lipids and nucleotides
in rapidly proliferating cancer cells4. Many cancer cells also
consume large amounts of glutamine, whose catabolism
replenishes intermediates for the mitochondrial trichloroacetic
acid (TCA) cycle (a process termed anaplerosis) and provides
nitrogen for the synthesis of non-essential amino acids and
nucleotides5.
To what extent are glucose and glutamine interchangeable as
carbon sources? In the absence of glucose, glutamine consump-
tion in some cells is sufficient to protect cell viability6–8. This
effect occurs via glutamine oxidation through the mitochondrial
TCA cycle. However, some cancer cells have limited metabolic
flexibility. First, the catabolism of glucose and glutamine in cancer
cells can be specialized to provide distinct benefits to the cell.
In proliferating glioblastoma cells, glucose metabolism is an
important source for cellular lipids, whereas glutamine
metabolism supports NADPH synthesis and replenishment of
the TCA intermediate oxaloacetate9. Second, oncogenic
reprogramming of metabolism can make cancer cells ‘addicted’
to either glucose or glutamine. Activation of the phosphoinositide
3-kinase (PI3K)-Akt pathway enhances glucose consumption and
glycolysis, and makes cancer cells highly susceptible to cell death
following glucose withdrawal10. The proto-oncogene MYC
stimulates glutamine metabolism and makes cells highly
dependent on glutamine to prevent apoptosis11,12. In these
cases, the rewiring of glucose or glutamine metabolism promotes
rapid cell growth and division but limits flexibility in the use of
alternative nutrients. Such metabolic reprogramming may
therefore generate unique vulnerabilities that can be exploited
for therapy13.
There is little known about the factors that limit the nutrient
flexibility of cells. To study this issue, we performed a genetic
screen in human haploid cells to identify factors that constrain
cells to utilization of glucose versus glutamine. We identified the
SLC3A2 and SLC7A11 subunits of the xCT amino acid
transporter (system xc–), which exports glutamate in exchange
for cystine, a precursor for synthesis of the antioxidant
glutathione. Downregulation of system xc– function markedly
improves cell viability under glucose-deficient/glutamine-replete
conditions, due to enhanced ability to use intracellular glutamate
to maintain respiratory chain activity. Furthermore, we identified
Nrf2, an important transcription factor for the SLC7A11 gene, as
a factor that limits the ability of breast cancer cells to utilize
glutamine instead of glucose. In cybrid cells harbouring
mitochondrial DNA (mtDNA) mutations, SLC7A11 is upregu-
lated and its inhibition improves survival in galactose medium,
where cellular bioenergetics rely primarily on mitochondrial
OXPHOS through glutamine oxidation14. Our results show that
system xc–, in addition to its well-known antioxidant role, is an
important metabolic regulator that affects the nutrient flexibility
of cells.
Results
A haploid genetic screen for glucose dependence. Many
immortalized cell lines show limited nutritional flexibility and are
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Figure 1 | Identification of SLC3A2 or SLC7A11 as factors limiting cell viability under glucose-deficient conditions. (a) Depiction of gene-trap insertions
found in the SLC3A2 and SLC7A11 genes, in Hap1 cells surviving glucose depletion. Black rectangles represent exons, and blue marks represent insertion
events. The number of gene-trap insertions from the unselected and selected populations was analysed by the one-sided Fisher exact test to calculate
P values. (b) Western blot analysis of SLC3A2 and SLC7A11 levels in WT Hap1 (WT), AC6 (SLC7A11 gene-trap clone) and AC24 (SLC3A2 gene-trap clone)
cells. (c) Quantification of glutamate release into the medium. Values were normalized to WT. Data represent the means±s.d. (n¼ 3); **Po0.01; unpaired
Student’s t-test. (d,e) Representative images (d) and quantification (e) of cell viability at 24 h after glucose withdrawal, with vehicle (DMSO) or 500mM
sulfasalazine (SASP). Scale bar, 200mm. Data represent the means±s.d. (n¼ 3).
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highly dependent on glucose as the primary carbon source.
We found that survival of the human haploid Hap1 cell line
requires glucose in the culture medium. To identify factors
involved in such ‘glucose addiction’, we performed a haploid
genetic screen15 to isolate mutants that survive in the complete
absence of glucose. We randomly mutagenized 1 108 Hap1 cells
with low multiplicity-of-infection with a retroviral gene trap
vector16 and cultured the mutagenized population in glucose-
deficient medium for 12 days. After the majority (499%) of cells
died, cells resistant to glucose depletion were recovered and
expanded in nutrient-rich medium. Gene-trap insertion sites
from the resistant population were identified using inverse-PCR-
based Illumina sequencing17. In the selected population, the genes
SLC3A2/4F2hc (399 distinct insertions) and xCT/SLC7A11
(39 insertions) were disrupted at high frequency by retroviral
integration (Fig. 1a). Remarkably, the protein products of these
genes are known to physically interact, with the SLC3A2 subunit
termed the heavy chain and the SLC7A11 subunit termed the
light chain, to form the amino acid antiporter known as system
xc– or the xCT antiporter18. The xCT antiporter is a cell-surface
amino acid transporter that exports glutamate in exchange for
cystine. This exchange is important for defence against cellular
reactive oxygen species (ROS), because cystine is the oxidized
dimer of cysteine, a critical precursor for synthesis of glutathione
(GSH), a major antioxidant19. For clarity, we refer to the
functional transporter as ‘system xc–’ or the ‘xCT antiporter’, and
the light chain subunit as SLC7A11.
To characterize the cellular consequences of these gene
disruptions, we isolated Hap1 clones with SLC3A2 and SLC7A11
gene-trap insertions. The SLC3A2 mutant, termed AC24, has a
gene-trap insertion in the second intron of SLC3A2 in the
expected orientation for gene disruption and shows no SLC3A2
expression. In addition, it has substantially lower SLC7A11
expression, which is expected because SLC3A2 must associate
with SLC7A11 to form a stable complex (Fig. 1b). The SLC7A11
mutant, termed AC6, has a gene-trap insertion in the
50 untranslated region of the first exon of SLC7A11 and shows
greatly decreased SLC7A11 expression at the protein (Fig. 1b) and
mRNA levels (Supplementary Fig. 1). SLC3A2 levels are largely
unaffected in AC6, probably because the SLC3A2 subunit is
shared by several amino acid transporters18. Both clones show
lower glutamate release into the media (Fig. 1c), confirming that
system xc– is functionally disrupted. Importantly, both clones
show highly improved viability under glucose-deficient
conditions (Fig. 1d,e). After 24 h of glucose deprivation, 470%
of the cells in both clones remain viable, whereas only 10% of
parental Hap1 cells survive. Consistent with this result, treatment
of Hap1 cells with sulfasalazine (SASP)20, a system xc– inhibitor,
improved the viability of WT Hap1 cells after glucose withdrawal
(Fig. 1d,e).
System xc– regulates cell viability during glucose withdrawal. To
independently confirm the results of the genetic screen, we used
short hairpin RNAs (shRNAs) to stably knockdown system xc– in
Hap1 cells (Fig. 2a). Because SLC3A2 has pleiotropic functions as
the common heavy chain for several amino acid transporters18,
we focused our knockdown efforts on the SLC7A11 subunit. Cells
containing either of two independent SLC7A11 shRNAs released
substantially less glutamate into medium (Fig. 2b). They showed
greatly improved viability after glucose withdrawal (Fig. 2c).
However, there was no change in proliferation rate in glucose-
containing media (Supplementary Fig. 2a).
Conversely, we wondered whether increasing the level of
system xc– in a cell line with low endogenous SLC7A11 would
sensitize cells to glucose withdrawal. Compared to Hap1 cells,
HeLa cells expressed almost undetectable levels of the SLC7A11
subunit (Fig. 2a) and exhibited low glutamate release into the
medium (Fig. 2b). Interestingly, control HeLa cells showed high
viability in the face of glucose removal (Fig. 2d). Overexpression
of the SLC7A11 subunit caused a large increase in glutamate
release (Fig. 2a,b) and greatly increased cell death during glucose
depletion (Fig. 2d). However, in glucose-containing media, there
was no change in the proliferation rate of SLC7A11-over-
expressing HeLa cells compared to the control (Supplementary
Fig. 2a). Thus, overexpression of SLC7A11 is sufficient to elicit
glucose addiction. Similar results were obtained using low glucose
(versus no glucose in the experiments above) culture conditions
(Supplementary Fig. 2b). In addition, neither knockdown nor
overexpression of SLC7A11 significantly changed cell viability
upon glutamine depletion (Supplementary Fig. 2c). Taken
together, these results indicate that the level of system xc– activity
controls the sensitivity of cells to glucose withdrawal.
The benefits of xCT depletion require glutamine metabolism.
Upon glucose withdrawal, glutamine becomes the primary carbon
source and its metabolism is critical for cell survival6–8. Once
imported, intracellular glutamine is converted into glutamate and
further to a-ketoglutarate, an intermediate of the TCA cycle.
Therefore, we speculated that cells with low system xc– activity
may be better able to maintain intracellular glutamate levels and
its metabolism into the TCA cycle. To test this idea, we directly
measured intracellular glutamate levels 1 h after glucose
withdrawal. SLC7A11 knockdown cells (Fig. 3a) and SLC3A2 or
SLC7A11 gene-trap mutants (Supplementary Fig. 3a) maintained
their intracellular glutamate level after glucose depletion far better
than control cells. Conversely, SLC7A11-overexpressing HeLa
cells had lower levels of intracellular glutamate than control cells
(Fig. 3b). Consistent with the known role of system xc– for GSH
synthesis, SLC7A11 knockdown reduced the level of intracellular
GSH in Hap1 cells, whereas SLC7A11-overexpressing HeLa cells
showed higher GSH levels than control cells (Supplementary
Fig. 3b).
We next asked whether glutamine/glutamate metabolism is
important for the enhanced cell survival of system xc–-deficient
cells during glucose withdrawal. We tested three compounds
[bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES,
glutaminase GLS1 inhibitor], aminooxyacetate (AOA, amino-
transferase inhibitor) and epigallocatechin gallate (EGCG,
glutamate dehydrogenase inhibitor)21 that inhibit enzymes
involved in conversion of glutamine to glutamate and then
a-ketoglutarate (Fig. 3c). Upon treatment with EGCG, Hap1 cells
disrupted for SLC7A11 (Fig. 3d; Supplementary Fig. 3c) or
SLC3A2 (Supplementary Fig. 3c) no longer show increased
viability under glucose deprivation, suggesting that glutamate
dehydrogenase (GDH) is critical for the effect. Because GDH
converts glutamate to a-ketoglutarate, we asked whether
a-ketoglutarate could reverse the inhibitory effect of EGCG.
Indeed, the inhibitory effect of EGCG was fully rescued by
supplementation with dimethyl a-ketoglutarate (dm-aKG), a
cell-permeable form of a-ketoglutarate, (Fig. 3e; Supplementary
Fig. 3d). Furthermore, dm-aKG supplementation during glucose
withdrawal greatly improved cell viability in wild-type (WT) and
control shRNA Hap1 cells (Fig. 3e; Supplementary Fig. 3d) and
SLC7A11-overexpressing HeLa cells (Fig. 2d), whereas additional
supplementation of glutamine into the medium did not
significantly improve cell viability (Supplementary Fig. 3e).
Therefore, these results suggest that conversion of glutamate to
a-ketoglutarate underlies the protective effect of system
xc– disruption under glucose-deficient conditions. The lack of
effect by BPTES or AOA suggests that GLS1 is not the primary
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glutaminase in Hap1 cells, and that GDH, rather than
aminotransferase, is important for conversion of glutamate to
a-ketoglutarate.
In the absence of glucose, mitochondrial OXPHOS (as the major
source of ATP synthesis) becomes essential for survival. Through
anaplerosis, glutamine-derived a-ketoglutarate replenishes inter-
mediates of the TCA cycle, which generates substrates to drive
OXPHOS21. We therefore tested whether the levels of system
xc– can regulate mitochondrial respiration. In the presence of
glucose, the oxygen consumption rate (OCR) of SLC7A11
knockdown Hap1 or overexpressing HeLa cells is comparable
with that of control cells (Supplementary Fig. 3f). However,
SLC7A11 knockdown cells show higher mitochondrial respiration
after 3 h of glucose depletion, whereas the OCR of SLC7A11-
overexpressing HeLa cells is lower than that of control cells under
glucose withdrawal (Fig. 3f).
Recent work has found that a-ketoglutarate generated from
consumed glutamine may undergo oxidative metabolism via the
‘forward’, clockwise TCA cycle or reductive carboxylation via a
‘reverse’ counter clockwise TCA reaction22–24. Relative flux
through the forward versus reverse TCA cycle may be
determined using stable 13C-isotope labelling (C5) of
extracellular glutamine and measuring label incorporation into
TCA cycle intermediates22,23,25. To determine whether
modulation of system xc– alters forward versus reverse TCA
cycle flux, SLC7A11 knockdown Hap1 or overexpressing HeLa
cells were cultured in the absence of glucose and with U-13C5-
glutamine (see Methods). Exposure to extracellular U-13C5-
glutamine resulted in near complete labelling (Mþ 5) of
intracellular glutamine and glutamate (Supplementary Fig. 3g).
Labelled glutamate entered the TCA via anaplerotic reaction to
a-ketoglutarate with Mþ 4 labelling of the forward TCA
intermediates succinate, fumarate, malate and citrate (Fig. 3g).
The Mþ 5 label of citrate (reductive TCA product) was observed
to a much lesser degree (B8:1 Mþ 4:Mþ 5 citrate), indicative of
low reverse TCA flux. Importantly, the relative degree of forward
versus reverse flux was unaltered with either knockdown or
overexpression of SLC7A11.
xCT regulates dependence of breast cancer cells on glucose. To
extend our observations on the negative effect of system xc– on
glutamine metabolism and respiration, we analysed gene
expression data for 947 cancer cell lines from the Cancer Cell Line
Encyclopedia (CCLE) project26. For each cancer type,
we categorized 15–20 cancer cell lines as high and low
SLC7A11 expressing and performed gene set enrichment
analysis between these two groups. We found that genes related
to OXPHOS were enriched in the low SLC7A11-expressing
groups, especially in lung (P value¼ 0.018) and breast cancer cell
lines (P value¼ 0.039). Moreover, analysis of 59 breast cancer
cells showed a marked and selective negative correlation between
the expression of SLC7A11 and mitochondrial OXPHOS genes
(Supplementary Fig. 4a,b). This observation suggests that most
breast cancer cells with low SLC7A11 expression have an
expression profile consistent with upregulation of the OXPHOS
machinery, and vice versa.
We chose two breast cancer cell lines, Hs578T and SK-BR-3, as
representative of high and low SLC7A11 expressing cell lines,
respectively (Supplementary Fig. 4a). Consistent with the CCLE
expression data, Hs578T cells showed a high expression level of
SLC7A11 and active release of glutamate into medium, whereas
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Figure 2 | System xc
 negatively impacts Hap1 and HeLa cell viability after glucose withdrawal. (a) Western blot analysis of SLC7A11 protein levels in
SLC7A11 knockdown Hap1 and SLC7A11-overexpressing HeLa cells. (b) Quantification of glutamate release into the medium. Data represent the means±s.d.
(n¼4); **Po0.01; unpaired Student’s t-test; scr, scrambled shRNA. (c,d) Cell viability at 24 h after glucose withdrawal. SLC7A11 knockdown Hap1 cells
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Data represent the means±s.d. (n¼ 3); vector: empty vector.
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SK-BR-3 cells showed low SLC7A11 expression and no detectable
release of glutamate (Fig. 4a; Supplementary Fig. 5a). We also
determined the metabolic status of Hs578T and SK-BR-3 cells by
measuring the activities of OCR and glycolysis (extracellular
acidification rate (ECAR)). Hs578T cells showed lower OCR and
a lower OCR/ECAR ratio than SK-BR-3 (Fig. 4b,c), suggesting
that Hs578T cells are more dependent on glycolysis than
SK-BR-3. Most Hs578T cells, like Hap1 cells, died upon glucose
withdrawal (Fig. 4d), whereas SK-BR-3 cells were resistant
(Fig. 4e). Hs578T cells depleted for SLC7A11 showed decreased
glutamate release into medium (Supplementary Fig. 5a) and
more effectively maintained intracellular glutamate levels under
glucose depletion (Supplementary Fig. 5b). Importantly, SLC7A11
knockdown greatly improved Hs578T cell viability during glucose
withdrawal (Fig. 4d). However, Hs578T cells lacking SLC7A11
had higher cellular ROS levels than control cells, consistent
with its role in antioxidant defence (Supplementary Fig. 5c).
Conversely, cells overexpressing SLC7A11 had lower ROS levels
(Supplementary Fig. 5c). The survival of SLC7A11 knockdown
Hs578T cells during glucose withdrawal was abolished by EGCG
and BPTES, again implying that production of a-ketoglutarate
from glutamate is critical (Fig. 4d). As expected, the detrimental
effects of EGCG or BPTES treatment were fully reversed by dm-
aKG supplementation (Fig. 4d). The differential effect of BPTES
(compare Fig. 4d with Fig. 3d) implies that GLS1 is the primary
glutaminase in Hs578T cells but not Hap1 cells.
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Overexpression of SLC7A11 in SK-BR-3 cells increased
glutamate release (Supplementary Fig. 5a) and concomitantly
reduced the ability to maintain intracellular glutamate under
glucose-deficient conditions (Supplementary Fig. 5b). SLC7A11
overexpression caused substantial SK-BR-3 cell death after
glucose withdrawal. Cell death was rescued by addition of
dm-aKG, suggesting that overexpression of SLC7A11 leads to a
deficiency of a-ketoglutarate under glucose-deficient conditions
(Fig. 4e).
Hs578T cells with SLC7A11 knockdown were able to maintain
their respiratory activity for prolonged periods after glucose
withdrawal (Supplementary Fig. 5d). Conversely, SK-BR-3 cells
overexpressing SLC7A11 showed a steep decline in OCR under
the same regiment. Taken together, these results indicate that
system xc– in breast cancer cells regulates intracellular glutamate
flux into the TCA cycle and increases sensitivity to glucose
withdrawal.
Nrf2 operates upstream of SLC7A11. Nrf2 (nuclear factor
erythroid 2-like 2, NFE2L2) is a key transcription factor that
upregulates many cytoprotective genes involved in oxidative
stress27. Because SLC7A11 is a known target gene of Nrf2
(ref. 27), we examined the correlation of Nrf2 and SLC7A11
expression in cancer cells. Nrf2 expression is positively correlated
with SLC7A11 expression across 59 breast cancer cell lines
(R¼ 0.5688), as well as all 947 cancer cell lines (R¼ 0.4306) in the
CCLE expression data. Moreover, Nrf2 target gene expression
shows high correlation with SLC7A11 expression across 947
cancer cell lines. The correlation coefficient (R) between SLC7A11
and NRF2 target genes are: NQO1 (þ 0.4179), GCLC (þ 0.3283),
GCLM (þ 0.3944) and TXNRD1 (þ 0.4321).
These correlations suggest that Nrf2 supports SLC7A11
expression in a subset of cancer cells. To test this idea, we
knocked down Nrf2 in Hs578T and MDA-MB-231 breast cancer
cells, two high expressors of SLC7A11. Nrf2 knockdown caused a
marked decrease in SLC7A11 expression (Fig. 5a,b,e) and reduced
glutamate release (Fig. 5c,f). Importantly, Nrf2-depleted cells
showed greatly improved viability during glucose withdrawal
(Fig. 5d,g). Again, this change in viability is dependent on
glutamate metabolism, because treatment with EGCG abolished
the pro-survival effect of Nrf2 knockdown (Fig. 5d). In addition,
a-ketoglutarate supplementation was sufficient to promote cell
survival, even in the presence of EGCG.
To examine the effect of Nrf2 upregulation, we treated cells
with dimethyl fumarate (DMF), a cell-permeable Nrf2 activator28.
DMF treatment caused MDA-MB-231 cells to highly induce
SLC7A11 expression and glutamate release (Fig. 5e,f). Moreover,
cells pretreated with DMF showed substantially reduced viability
during glucose depletion compared to control cells (Fig. 5g). We
ruled out off-target effects by showing that these outcomes of
DMF treatment were dependent on both SLC7A11 and
Nrf2 (Fig. 5f,g). Taken together, these results indicate that the
Nrf2–SLC7A11 axis regulates glutamate metabolism, the
dependence of cancer cells on glucose, and their ability to
utilize glutamine as an alternative carbon source. Importantly, it
suggests that adaptation to oxidative stress in cancer cells can
compromise nutrient flexibility, particularly through the
enhancement of a glucose addiction phenotype.
xCT regulates mitochondrial function in mtDNA-mutant cells.
Our findings above indicate that cells with system xc– upregulation
due to oxidative stress may have restricted nutrient flexibility due
to impaired glutamine metabolism. Inhibition of the mitochon-
drial respiratory chain can increase reactive oxygen species29,30.
We found that SLC7A11 expression was induced by drugs that
block mitochondrial function, especially rotenone and
oligomycin, which inhibit complex I (NADH dehydrogenase)
and V (ATP synthase) of the OXPHOS machinery, respectively
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(Supplementary Fig. 6a). Consistent with these pharmacological
results, SLC7A11 was upregulated in cybrid cells containing
homoplasmic mtDNA mutations in the ND1 subunit of complex
I or subunit ATP6 of complex V (NARP) (Fig. 6a)30,31. The
SLC7A11 induction was particularly marked in the NARP cell
line, which has been reported to have high levels of ROS and
induction of the mitochondrial ROS-scavenging enzyme
MnSOD30. SLC7A11 induction in the NARP cybrid cells was
highly dependent on the Nrf2 and Atf4 transcription factors
(Supplementary Fig. 6b) and could be suppressed by treatment
with the antioxidant N-acetylcysteine (Supplementary Fig. 6c).
We investigated whether these compensatory changes in
system xc– expression affect cellular metabolism in the cybrid
cells. Consistent with their higher expression of SLC7A11, the
ND1 and NARP cybrids had lower intracellular glutamate levels
(Fig. 6b). Inhibition of system xc– by SLC7A11 knockdown or a
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potent inhibitor, erastin, increased intracellular glutamate in ND1
and NARP cells. Similarly, intracellular a-ketoglutarate, a product
of glutamate metabolism, was also increased by SLC7A11
inhibition (Supplementary Fig. 6d). It has long been known that
cells with OXPHOS defects survive poorly on galactose-contain-
ing medium, which forces a higher demand for OXPHOS as the
source of ATP generation32. The ND1 and NARP-mutant
cybrids, unlike the isogenic WT 143B cells, were not able to
survive in galactose-containing medium (Fig. 6c; Supplementary
Fig. 6e). However, SLC7A11 knockdown or erastin treatment
strongly rescued the viability of ND1 and NARP cybrids in
galactose medium. The effect was most marked in the NARP
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cybrids, which showed a much greater induction of SLC7A11
(Fig. 6c).
This increase in cell viability was correlated with striking
normalization of mitochondrial morphology. Our group pre-
viously reported that WT cells elongate their mitochondria under
medium conditions that require enhanced OXPHOS activity,
whereas cells with mtDNA mutations instead fragment their
mitochondria33. Consistent with this result, ND1 and NARP
cybrids showed marked mitochondrial fragmentation after 24 h of
galactose culture. In contrast, cybrids with SLC7A11 knockdown
or erastin treatment showed substantial elongation of
mitochondria when the carbon source in the medium was
switched from glucose to galactose (Fig. 6d; Supplementary
Fig. 6f). SLC7A11 knockdown did not change the levels of several
mitochondrial dynamics proteins, including Opa1, Mfn1 and
Drp1 (Supplementary Fig. 6g). Furthermore, the SLC7A11
knockdown cells showed higher respiration activity than
control-mutant cells (Fig. 6e). Taken together, these results
suggest that inhibition of system xc– in mtDNA-mutant cybrids
improves mitochondrial morphology and respiration, resulting in
markedly enhanced survival in galactose medium.
Discussion
System xc– is a cystine–glutamate antiporter composed of the light
chain subunit xCT/SLC7A11 and the heavy chain subunit
SLC3A2/CD98hc. Previous studies have focused on the role of
this antiporter in cellular redox homoeostasis, because it imports
cystine, the rate-limiting precursor for synthesis of the anti-
oxidant glutathione19. The importance of this function is
emphasized by the estimate that one-third to one-half of the
glutamine taken up by cultured human fibroblasts is used to drive
import of cystine34. Induction of system xc– is thought to be
beneficial to cancer cells, because these cells often have elevated
levels of ROS. Expression of SLC7A11 in tumour cells has been
linked to resistance to anti-cancer drugs35, induction of tumour
growth, cancer cell proliferation, survival36–38, cell invasion and
tumour metastasis39,40. As a result, the xCT antiporter has been
suggested to be a promising drug target in aggressive breast
tumours38.
However, our studies identify a new aspect of xCT antiporter
function. Due to its glutamate export activity, xCT antiporter
activity is a key metabolic factor that regulates the nutrient
requirements of cultured cells (Fig. 6f). By exporting large
amounts of glutamate, an active xCT antiporter system
suppresses glutamate-dependent processes in the cell, including
mitochondrial respiration. As a result, cells with high system
xc– activity have limited viability when glucose is removed
and glutamine becomes the predominant carbon source.
Consistent with this notion, we show in multiple cell lines
that xCT antiporter activity is responsible for glucose addiction.
When SLC7A11 is disrupted, these cell lines show greatly
enhanced survival with glutamine as the major carbon
source. This survival depends on conversion of glutamine to
glutamate and then a-ketoglutarate, a TCA cycle component.
Conversely, overexpression of SLC7A11 is sufficient to make
HeLa and SK-BR3 cells highly dependent on glucose versus
glutamine.
We show that, through its effect on SLC7A11 levels, Nrf2 is
also a factor that can regulate glutamine metabolism and nutrient
flexibility in some breast cancer cells. Consistent with our
observation that Nrf2 upregulates xCT function, constitutive
expression of Nrf2 redirects glutamine flux from the TCA cycle
into GSH and NADPH production41. We show that high Nrf2
expression limits cells to utilization of glucose, and that removal
of Nrf2 enables cells to utilize glutamine more efficiently by
maintaining intracellular glutamate levels. These functions are
dependent on the Nrf2 target gene SLC7A11.
Why do some tumour cells upregulate Nrf2 and system xc–, if
doing so results in glucose addiction? As a critical component of
the antioxidant response, Nrf2 is activated by the higher levels of
oxidative stress found in tumour cells. Oncogenes such as Ras,
Raf and Myc have been shown to increase Nrf2 transcription as a
mode of reducing ROS42. In addition, somatic mutations in
tumour cells can directly upregulate Nrf2 levels. Normally, Nrf2
levels are kept low by ubiquitination via the E3 ubiquitin ligase
adaptor Kelch-like ECH-associated protein 1 (Keap1). Somatic
mutations in Nrf2 or Keap1 can abolish Keap1-dependent
degradation of Nrf2, resulting in its accumulation and
translocation to the nucleus to upregulate antioxidant response
genes43. Due to its antioxidant effects, Nrf2 expression is critically
correlated with tumour growth, drug resistance and poor
prognosis in some human cancers44. Therefore, we propose the
following framework for the dual roles of system xc– in antioxidant
defence and glutamine metabolism. In the face of high oxidative
stress, many cancer cells turn on the Nrf2–SLC7A11 axis to
maintain redox homoeostasis. However, a metabolic consequence
of high Nrf2–SLC7A11 expression is reduced efficiency of
glutamine-dependent processes that drive mitochondrial
respiration. This upregulation of system xc– contributes to
glucose addiction, but is beneficial as long as glucose is plentiful.
Compensatory system xc– upregulation also places constraints
on the metabolism of cells containing mtDNA mutations. Cybrids
with mtDNA mutations, particularly in complex V, show
enhanced expression of SLC7A11, likely in response to increased
ROS levels30. This response has antioxidant benefits but appears
to be maladaptive in terms of mitochondrial function. The
resulting metabolic rewiring exacerbates the defect in the
OXPHOS pathway in cybrids with ND1 and NARP mutations.
These homoplasmic cybrids have a 50% reduction in OXPHOS
activity30,31. They grow in standard high glucose medium but die
rapidly when switched to galactose medium, a characteristic
phenotype of cells in which glutamine metabolism and OXPHOS
is limiting. Remarkably, when SLC7A11 is reduced, these cells are
able to survive, and this phenotypic rescue is associated with
enhanced mitochondrial respiration and normalization of
morphology. These results suggest, in principle, that system
xc– inhibition may have therapeutic potential in mtDNA disease
associated with oxidative stress and maladaptive upregulation of
SLC7A11. Such treatments would likely need to be combined
with antioxidant supplementation to replace that aspect of system
xc– function. To test this idea, future studies with animal models of
mtDNA diseases will be needed.
Methods
Reagents and antibodies. Dimethyl sulfoxide (DMSO), dm-aKG, dimethyl
fumarate (DMF), BPTES, aminooxyacetate (AOA), epigallocatechin gallate
(EGCG), erastin, and sulfasalazine (SASP) were obtained from Sigma-Aldrich.
Antibodies to the following proteins were used: SLC7A11 (1:2,000, Abcam,
ab37185; 1:5,000, Cell Signaling, 12691), SLC3A2 (1:3,000, Santa Cruz BioTech,
SC-9160), Hsp60 (1:10,000, Santa Cruz BioTech, sc-1052), Actin (1:10,000, Sigma,
A2103). The uncropped scans for key western blots are provided (Supplementary
Fig. 7).
Cell culture. HeLa (ATCC), 293 T (ATCC), SK-BR-3 (Raymond Deshaies,
Caltech), MDA-MB-231 (Raymond Deshaies, Caltech), 143B (Giovanni Manfredi,
Weill Medical College), ND1 (Valerio Carelli, University of Bologna), NARP
(Giovanni Manfredi, Weill Medical College) and Hs578T (ATCC) cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum. Hap1 (Thijn Brummelkamp, Netherlands Cancer Insti-
tute) cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM)
supplemented with 10% fetal bovine serum and additional glutamine. For glucose
deprivation, cells were initially incubated overnight in DMEM lacking glucose,
pyruvate, and glutamine (Invitrogen, A14430) supplemented with 10% dialysed
FBS, 10mM glucose and 2mM (breast cancer cells and mtDNA cybrid cells) or
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6mM glutamine (Hap1). The glucose-containing medium was changed to glucose-
deficient medium (DMEM A14430þ 10% dialysed FBSþ 1mM glutamine). For
oxidative culture, galactose-containing medium was generated by DMEM solution
lacking glucose, pyruvate and glutamine supplemented with 10% dialysed FBS,
10mM galactose and 2mM glutamine.
Haploid genetic screen. Gene-trap vector, pGTpuro, was generated by replacing
the GFP gene of pGTen2-ACTB16 with the puromycin resistance gene. Prior to
gene-trap induced random mutagenesis, Hap1 cells were enriched for the haploid
karyotype by subcloning. The production of gene-trap virus and mutagenesis of
Hap1 cells were performed as previously described16. Overall, 108-mutagenized
Hap1 cells were incubated in the glucose-deficient medium for 12 days. Cells
resistant to glucose depletion were recovered in IMDM medium and formed
B1,200 colonies. Genomic DNA was extracted from the unselected and glucose
depletion-selected population, and restricted with MseI (New England Biolabs,
R0525) or NlaIII (New England Biolabs, R0125). After self-ligation, genomic DNA
was used as template for inverse-PCR. The 50 primer was:
50-CAAGCAGAAGACGGCATACGACTGTGTTTCTGTATTTGTCTG-30 for
MseI-digested DNA, or 50-CAAGCAGAAGACGGCATACGACCCAGGTTAAG
ATCAAGGTC-30 for NlaII-digested DNA. The 30 primer was:
50-AATGATACGGCGACCACCGAGATCTACACTCTTTC CCTACACGA
CGCTCTTCCGATCTTGCCAAACCTACAGGTGG-30 . Gene-trap insertion sites
were identified using inverse-PCR based Illumina HiSeq 2000 sequencing
(Illumina, San Diego, CA, USA)17. Read alignment to the human hg19 genome and
computational comparison of aligned reads between unselected and selected
population were performed using Bowtie2, the Integrated Genome Browser and
Galaxy, a web-based genome analysis tool45–47.
ROS measurement. Cells were incubated with 10 mM 20, 70-dichlorofluorescin
diacetate (DCFH-DA) in DMEM lacking phenol red for 30min at 37 C and
washed with phosphate-buffered saline (PBS). Trypsinized cells were subjected to
fluorescence analysis using an Accuri C6 flow cytometer (BD Bioscience).
Real-time RT-PCR. Total RNA was extracted from the indicated cells using the
SV total RNA isolation kit (Promega) and then reverse transcribed into cDNA
using Superscript III First Strand Synthesis kit (Invitrogen). Real-time PCR was
performed using the Brilliant III Ultra-Fast SYBR Green QPCR Master Mix
(Agilent Technologies) and the CFX96 real-time system (Bio-Rad). Relative fold
enrichments of target genes were calculated using the comparative CT method48.
SLC7A11 overexpression. For SLC7A11 expression, pQCXIP (Clontech) was
digested with BamHI, blunt-ended with Klenow polymerase (New England
Biolabs), and ligated with the SLC7A11 gene PCR-amplified from a human cDNA
library. Cell lines were infected with control retrovirus or retrovirus expressing
SLC7A11.
Stable shRNA. For shRNA-mediated stable knockdown of SLC7A11 or NRF2, the
indicated cell lines were infected with retrovirus expressing shRNA from the
human H1 promoter. The targeted sequences were: xCT-Sh1 (50-GCTGAATTG-
GGAACAACTATA-30), xCT-Sh3 (50-GCAGTTGCTGGGCTGATTTAT-30),
NRF2-Sh1 (50-GGTTGAGACTACCATGGTTCC-30), ATF4-Sh (50-GCCAAG-
CACTTCAAACCTCAT-30) and scrambled shRNA (50-CGTTAATCGCGTA-
TAATACGC-30).
Cell viability under glucose depletion. Cells were incubated in glucose-deficient
medium (DMEM A14430þ 10% dialysed FBSþ 1mM glutamine) for 24 or 48 h.
Attached cells at 0, 24 or 48 h were trypsinized, resuspended in fresh medium, and
counted with an Accuri C6 flow cytometer (BD Bioscience).
Immunostaining for mitochondrial morphology. Cells were fixed in 10% for-
maldehyde, permeabilized in 0.1% Triton X-100 and immunostained with antibody
to HSP60 (1:300, Santa Cruz BioTech). Immunofluorescent images were obtained
with a Zeiss LSM 710 confocal microscope (Carl Zeiss). Mitochondrial morphology
was scored in triplicates of 100 cells per sample.
Isotope tracing and mass spectrometry. For determination of relative oxidative
versus reductive TCA flux, steady state isotope labelling of TCA cycle intermediates
was employed, as previously described22,23,25. Hap1 and HeLa cells with silencing
and overexpression, respectively, of xCT were cultured in glucose free media
containing 2mM U-13C5-glutamine (Cambridge Isotope Laboratories) for 8 h.
Cells were washed quickly with PBS 3 and pelleted. Cell pellets were resuspended
in 400 ml of ice-cold 80:20 methanol:water, and vortexed for 60 s followed by three
freeze-thaw cycles, with alternating 37 C and  80 C liquid baths in 45 s intervals.
To ensure complete cell lysis, samples were again vortexed for 30 s and sonicated
for 2 min. Samples were then centrifuged at 14,000 g 10min at 4 C, and the
supernatants (375 ml) were collected and dried down in vacuo using a vacuum
concentrator. Samples were re-suspended in 80:20 methanol:water according to
their cell counts with 50ml being the volume assigned to the lowest cell count
sample with subsequent samples scaled linearly. Resuspended samples were mixed
by aspiration, sonicated for 2min, vortexed for 30 s, centrifuged at
14,000 g 10min at 4 C and supernatants were transferred to LCMS vials
containing a 200 ml glass insert. LC–MS/MS-based metabolomics analysis was
performed using an Thermo QExactive orbitrap mass spectrometer coupled to a
Thermo Vanquish UPLC system. Chromatographic separation of metabolites was
achieved using a Phenomenex Luna NH2 aminopropyl column (2.1 100mm,
3 mm) maintained at 35 C and running a 25min linear elution gradient starting
from 95:5 acetonitrile: 20mM ammonium acetate pH 9.6–5:95 acetonitrile: 20mM
ammonium acetate pH 9.6, similar to as previously described49. An injection
volume of 6 ml, which contained metabolic material from B80,000 cells, was used
for all sample injections. The mass spectrometer was operated in negative ion mode
running data-dependent MS2 acquisition using a heated electrospray ionization
source operated under the following settings: sheath gas flow of 40U, auxiliary gas
flow of 15U, sweep gas flow of 2U, spray voltage of  2.5 kV, capillary
temperature of 265 C, aux gas temp of 350 C and S-lens RF at 45. For MS1 scan
events, a scan range of m/z 67–1,000, mass resolution of 70,000, AGC target at 3e6
and max inject time of 100ms was used. For MS2 acquisition, a mass resolution of
17.5 k, AGC target at 1e6 and inject time of 50ms was used. Collected data was
imported into the mzMine 2.20 software suite for analysis. Pure standards were
used for identification of metabolites through manual inspection of spectral peaks
and matching of retention time and MS1 accurate mass, with confirmation of
identification through comparison to MS/MS fragmentation patterns.
Glutamate, glutathione and a-ketoglutarate level assay. The Amplex Red
Glutamate Assay Kit (Molecular Probes), GSH/GSSG Ratio Detection Assay Kit
(abcam) and the Alpha-Ketoglutarate Colorimetric/Fluorometric Assay Kit
(BioVision) were used for detection of extracellular glutamate released into the
medium and intracellular glutamate and a-ketoglutarate in cell lysates. After cells
were incubated in fresh glucose-deficient medium for 1 or 2 h, 50 ml medium was
taken for extracellular glutamate measurement. For intracellular glutamate and
a-ketoglutarate, trypsinized cells were resuspended in 0.1M Tris-HCl (pH 7.4) and
lysed by sonication with three cycles of 10 s on and 30 s off at 20% amplitude. Cell
lysates were used for intracellular glutamate, total glutathione and a-ketoglutarate
measurement. Values were normalized to protein concentrations of cell lysates.
OCR and ECAR measurements. OCR and ECAR of the indicated cell lines were
analysed using a Seahorse Bioscience XF96 Extracellular Flux Analyzer (Seahorse
Bioscience). Cells were plated into Seahorse tissue culture 96-well plates in DMEM
solution lacking glucose, pyruvate, and glutamine (Invitrogen, A14430) supple-
mented with 10% dialysed FBS, 10mM glucose or galactose and 2 or 6mM
glutamine and incubated overnight. Prior to measurement, cells were equilibrated
in DMEM lacking bicarbonate (Sigma-Aldrich Catalogue #D5030) supplemented
with 10% dialysed FBS and the indicated concentration of glutamine±10mM
glucose. For OCR and ECAR measurements, four consecutive readings were
performed at each time point.
Statistical analysis. Statistical significances (P value) of gene-trap insertions on
SLC3A2 or SLC7A11 gene were calculated using the one-sided Fisher exact test.
Results of cell culture experiments were collected from three or four independent
cultures for each sample. Data are presented as means±s.d. The unpaired
Student’s t-test was used to calculate P values.
Data availability. All data presented in this study are available from the authors
upon request.
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